We are live on ! Find out more
CGTX icon

Cognition Therapeutics

47 hedge funds and large institutions have $12.9M invested in Cognition Therapeutics in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 5

27% more funds holding

Funds holding: 3747 (+10)

3% less capital invested

Capital invested by funds: $13.3M → $12.9M (-$371K)

5.41% less ownership

Funds ownership: 23.59%18.18% (-5.4%)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
47
Holders Change
+10
Holders Change %
+27.03%
% of All Funds
0.68%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
9
Reduced
10
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
ASN
51
Advisory Services Network
Georgia
-$4.63K -2,500 Closed
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
-$403 -195 -98%

CGTX Hedge Fund Activity: Q1 2024 in Review

47 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q1 2024, worth a combined $12.9M — down 2.8% from $13.3M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CGTX positions and 5 closed out — a net gain of 10 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was AWM Investment Company, opening a new position worth an estimated $1.34M. The largest seller was Pathstone Holdings, exiting entirely with an estimated $4.08M sold.

  • 47 institutional investors held Cognition Therapeutics (CGTX) as of Q1 2024, up from 37 in Q4 2023.
  • Funds reported $12.9M of Cognition Therapeutics stock for Q1 2024, down 2.8% quarter-over-quarter.
  • 15 funds opened new Cognition Therapeutics positions in Q1 2024 and 5 closed out, a net change of +10 holders.
  • The largest Cognition Therapeutics buyer in Q1 2024 was AWM Investment Company, an estimated $1.34M added.
  • The largest Cognition Therapeutics seller in Q1 2024 was Pathstone Holdings, an estimated $4.08M sold.

Based on aggregated 13F filings for Q1 2024.